FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.

Overview of attention for article published in Clinical Cancer Research, December 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

So far, Dimensions has found 63 publications that cite this research output.

Article in Radiation Physics and Chemistry (October 2024)

Article in Bioengineering (July 2024)

Article in Biomedicine & Pharmacotherapy (July 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.